SEB har mod betaling udarbejdet denne analyse af Curasight:
Higher ambitions
Curasight has announced that it will expand its focus area for its two modalities, uTRACE (diagnostics) and uTREAT (therapy). Two recent publications made by researchers at the Danish Rigshospitalet underscored the potential of Curasight’s technology when applied to Neuroendocrine tumours (NET), as well as head and neck cancer. Curasight will invest in these two indications, which adds further to its pipeline.
Goal is to get to the market by 2026
Curasight aims to have the two new uTRACE (diagnostic) indications, mentioned above, approved by the US Food and Drug Administration (FDA) by 2026. While this sounds ambitious, we note that a diagnostic agent is not required to go through the same extensive clinical development program as a therapeutic agent. We seek to learn more about the actual phase III plans with the two new indications for uTRACE. We expect additional details before the end of Q1 2022.
Få vores øvrige investeringsnyheder direkte i din indbakke. Tilmeld dig vores gratis daglige nyhedsbrev her:
Få dagens vigtigste
økonominyheder hver dag kl. 12
Bliv opdateret på aktiemarkedets bevægelser, skarpe indsigter
og nyeste tendenser fra Økonomisk Ugebrev – helt gratis.
